Loading...
Loading...
reported stronger-than-expected earnings for the second quarter and raised its profit forecast for the full year.
The New York-based company posted a quarterly loss of $130 million, or $0.08 per share, versus a year-ago profit of $333 million, or $0.20 per share. Excluding special items, the company earned $0.53 per share.
Its revenue climbed 7 percent to $4.16 billion. However, analysts were expecting earnings of $0.36 per share on revenue of $3.71 billion.
The average estimate among 24 Estimize users was for earnings of $0.38 per share and revenue of $3.76 billion.
U.S. revenue declined 3 percent to $1.8 billion in the quarter, while international revenue rose 17 percent.
Yervoy sales declined 8 percent to $296 million in the recent quarter.
Its gross margin as a percentage of revenues widened to 75.7 percent in the quarter, from 74.5 percent in the year-ago period.
Research and development expenses gained 31 percent to $1.9 billion in the quarter, while marketing, selling and administrative expenses rose 2 percent to $968 million.
"We had a very good quarter, with strong sales across our portfolio, encouraging results from clinical trials and important regulatory milestones," said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. "I am excited by our progress in Immuno-Oncology as we continue to advance our leadership position and transform cancer treatment. As our Immuno-Oncology data continues to emerge, it is clear we have a tremendous opportunity, and we are making the right strategic investments to capitalize on the full potential of our portfolio."
For the full year, Bristol-Myers now projects earnings of $1.70 to $1.80 per share, versus its previous outlook of $1.60 to $1.70 per share.
Bristol-Myers Squibb shares rose 1.77 percent to $70.60 in pre-market trading.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in